Ask AI

Precision Pathways: Incorporating Recent Advances in SCLC Treatment When Time Is of the Essence

Improve your ability to integrate new treatment strategies that use immunotherapies and targeted agents into practice using an individualized approach based on updated guidelines for the treatment of limited-stage and extensive-stage small-cell lung cancer (SCLC) through certified Medical Minute modules with accompanying downloadable slides and an Interactive Decision Support Tool.

Share

Program Content

Activities

Therapeutic Advancements in LS SCLC
Enhancing Outcomes in Limited-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements 
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: September 18, 2025

Expires: March 17, 2026

Activities

Therapeutic Advancements in LS SCLC
Enhancing Outcomes in Limited-Stage Small-Cell Lung Cancer With Recent Therapeutic Advancements
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 18, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.